Sucralfate is NOT Recommended for Dyspepsia
Sucralfate should not be used to treat functional dyspepsia, as it is not included in evidence-based treatment guidelines and lacks consistent efficacy data. The most recent and authoritative British Society of Gastroenterology guidelines from 2022 do not recommend sucralfate for dyspepsia management at any treatment stage 1.
Why Sucralfate Is Not Recommended
The 2022 BSG guidelines explicitly state they "have only recommended medications with good evidence that they are more efficacious than a placebo" and "have not recommended tests or treatments where the evidence is that they do not help, are harmful, or where there is not enough evidence" 1. Sucralfate's absence from these comprehensive guidelines is telling.
Evidence Against Sucralfate
The research evidence for sucralfate in dyspepsia is contradictory and ultimately unconvincing:
- A 2003 systematic review found sucralfate was NOT statistically significantly superior to placebo for non-ulcer dyspepsia 2
- A 1993 double-blind placebo-controlled trial showed no difference between sucralfate and placebo (68% vs 69% improvement respectively) 3
- A 2003 review concluded "sucralfate is unlikely to be effective" 4
- A 2025 analysis questioned why sucralfate continues to be prescribed given its "low clinical value" despite high economic burden 5
While two older studies from 1987 and 1992 showed positive results 6, 7, these findings have not been consistently replicated and are contradicted by more rigorous subsequent research.
What SHOULD Be Used Instead
First-line treatments with strong evidence include:
Proton pump inhibitors (PPIs) - Strong recommendation with high-quality evidence. Use the lowest effective dose 1
H. pylori eradication - Strong recommendation with high-quality evidence for H. pylori-positive patients 1
H2-receptor antagonists - Weak recommendation with low-quality evidence, but still superior to sucralfate 1
Regular aerobic exercise - Strong recommendation 1
Second-line treatment:
- Tricyclic antidepressants (e.g., amitriptyline 10 mg daily, titrated to 30-50 mg) - Strong recommendation with moderate-quality evidence 1
Clinical Pitfall to Avoid
Do not continue prescribing sucralfate based on historical practice patterns. The FDA labeling for sucralfate indicates approval for duodenal ulcer treatment 8, not functional dyspepsia. Its mechanism (forming a protective barrier over ulcerated tissue) is not relevant to the pathophysiology of functional dyspepsia, which involves gut-brain axis dysfunction, visceral hypersensitivity, and altered motility 1.